Moderna to advance two Omicron vaccine candidates against newer variants
Cambridge: Moderna Inc said on Monday it was advancing two Omicron vaccine candidates for the fall, one designed against the BA.1 variant and another against the BA.4 and BA.5.
Vaccine makers including Moderna and rival Pfizer Inc are developing updated vaccines to target the fast-spreading Omicron subvariants BA.4 and BA.5, which have gained a foothold in the United States over recent weeks.
Moderna said its decision to develop the bivalent vaccines was based on different market preferences for shots against the subvariants.
Bivalent vaccines are designed to target two different coronavirus variants - the original variant from 2020 and the newer Omicron variants.
Moderna said new clinical data for its mRNA-1273.214 vaccine, designed to target the BA.1 variant, showed significantly higher neutralizing antibody responses against the fast-spreading BA.4 and BA.5 compared with the currently authorized booster.
The company's second booster candidate, mRNA 1273.222, is based on the BA.4/5 strain and is being developed in accordance with recent U.S. Food and Drug Administration advice.
Jefferies analyst Michael Yee said though the new data on the company's BA.1 subvariant-targeting booster shows better durability and antibody response, the original Omicron variant has already shifted in the United States and the FDA is likely to approve planned BA.4/5 boosters.
Read also: Moderna to establish mRNA Innovation and Technology Center in UK
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.